BioCentury | Jul 19, 2019
Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

...inhibitor AUM Biosciences Pte. Ltd. (Singapore) licensed exclusive rights to pan-PIM/PI3K/mTOR triple kinase inhibitors from Inflection Biosciences Ltd....
...Romeo, Assistant Editor avapritinib (blu-285) CD3xCD123 DART molecule, flotetuzumab (MGD006, S80880) mavacamten (SAR439152, myk-461) MYK-224 Blueprint Medicines Corp. Emmaus Life Sciences Inc. Inflection Biosciences Ltd. MacroGenics...
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Pim-1 (PIM1); Pim-2 (PIM2)

...has AZD1208 , a pan-PIM kinase inhibitor, in Phase I testing to treat hematologic malignancies. Inflection Biosciences Ltd....
BioCentury | Mar 16, 2015
Financial News

Inflection Biosciences completes venture financing

Inflection Biosciences Ltd. , Blackrock, Ireland Business: Cancer Date completed: 2015-03-09 Type: Venture financing Raised: EUR725,000 ($786,988) Investors: New investors; existing investors Note: The financing includes the conversion of EUR225,000 ($244,238) in previously issued loan notes....
BioCentury | Jul 29, 2013
Emerging Company Profile

Inflection: Pairing up PIM

...the clinic on its own. Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Inflection Biosciences Ltd....
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Spanish National Cancer Research Centre (CNIO), Madrid, Spain Sidebars Inflection Biosciences Ltd....
BioCentury | Jul 11, 2013
Translation in Brief

Translational tidbits

...undisclosed protein involved with DNA damage response and screening for compounds against an undisclosed target Inflection Biosciences Ltd....
BioCentury | Jun 10, 2013
Financial News

Inflection Biosciences completes venture financing

Inflection Biosciences Ltd. , Blackrock, Ireland Business: Cancer Date completed: 6/3/13 Type: Venture financing Raised: €450,000 ($585,000) Investors: Private investor; Enterprise Ireland WIR Staff...
BioCentury | Jun 10, 2013
Company News

Inflection Biosciences, Spanish National Cancer Research Centre (CNIO) deal

...development. Inflection, which was founded last year, hopes to start clinical testing in early 2015. Inflection Biosciences Ltd....
Items per page:
1 - 7 of 7
BioCentury | Jul 19, 2019
Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

...inhibitor AUM Biosciences Pte. Ltd. (Singapore) licensed exclusive rights to pan-PIM/PI3K/mTOR triple kinase inhibitors from Inflection Biosciences Ltd....
...Romeo, Assistant Editor avapritinib (blu-285) CD3xCD123 DART molecule, flotetuzumab (MGD006, S80880) mavacamten (SAR439152, myk-461) MYK-224 Blueprint Medicines Corp. Emmaus Life Sciences Inc. Inflection Biosciences Ltd. MacroGenics...
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Pim-1 (PIM1); Pim-2 (PIM2)

...has AZD1208 , a pan-PIM kinase inhibitor, in Phase I testing to treat hematologic malignancies. Inflection Biosciences Ltd....
BioCentury | Mar 16, 2015
Financial News

Inflection Biosciences completes venture financing

Inflection Biosciences Ltd. , Blackrock, Ireland Business: Cancer Date completed: 2015-03-09 Type: Venture financing Raised: EUR725,000 ($786,988) Investors: New investors; existing investors Note: The financing includes the conversion of EUR225,000 ($244,238) in previously issued loan notes....
BioCentury | Jul 29, 2013
Emerging Company Profile

Inflection: Pairing up PIM

...the clinic on its own. Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Inflection Biosciences Ltd....
...Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Spanish National Cancer Research Centre (CNIO), Madrid, Spain Sidebars Inflection Biosciences Ltd....
BioCentury | Jul 11, 2013
Translation in Brief

Translational tidbits

...undisclosed protein involved with DNA damage response and screening for compounds against an undisclosed target Inflection Biosciences Ltd....
BioCentury | Jun 10, 2013
Financial News

Inflection Biosciences completes venture financing

Inflection Biosciences Ltd. , Blackrock, Ireland Business: Cancer Date completed: 6/3/13 Type: Venture financing Raised: €450,000 ($585,000) Investors: Private investor; Enterprise Ireland WIR Staff...
BioCentury | Jun 10, 2013
Company News

Inflection Biosciences, Spanish National Cancer Research Centre (CNIO) deal

...development. Inflection, which was founded last year, hopes to start clinical testing in early 2015. Inflection Biosciences Ltd....
Items per page:
1 - 7 of 7